<DOC>
	<DOCNO>NCT00511992</DOCNO>
	<brief_summary>The purpose study evaluate tolerability intraperitoneal cisplatin intravenous paclitaxel Avastin define proportion patient able complete 6 cycle treatment .</brief_summary>
	<brief_title>Study Bevacizumab Followed Bevacizumab Consolidation Ovarian Cancer</brief_title>
	<detailed_description>Ovarian cancer lead cause death gynecologic cancer United States . The high death rate stem late presentation tumor spread beyond ovary time diagnosis . Ovarian cancer typically spread throughout peritoneal cavity . Three randomize clinical trial recently demonstrate superiority intraperitoneal ( IP ) intravenous platinum base chemotherapy optimally debulked advance ovarian cancer . The success Bevacizumab metastatic colorectal cancer lead trial evaluate ' efficacy advance ovarian cancer . Based mechanism action Bevacizumab , may benefit extended therapy agent .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carcinosarcoma</mesh_term>
	<mesh_term>Mixed Tumor , Mullerian</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients stage II III epithelial ovarian carcinoma , primary peritoneal carcinoma , ovarian carcinosarcoma . Adequate bone marrow , renal , hepatic function Patients must enter twelve week postoperatively Patients epithelial ovarian carcinoma low malignant potential ( borderline carcinoma ) . Stage IV suboptimally debulked disease follow primary cytoreductive surgery Patients receive prior radiotherapy chemotherapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Gynecologic Cancer</keyword>
	<keyword>Ovarian Carcinoma</keyword>
	<keyword>Peritoneal Carcinoma</keyword>
	<keyword>IP chemotherapy</keyword>
	<keyword>Intraperitoneal</keyword>
	<keyword>Avastin</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>